Racemization and degradation of thioridazine and thioridazine 2-sulfone in human plasma and aqueous solutions

Chirality

Volumn 15, Issue 6, 2003, Pages 479-485

  Masetto de Gaitani, Cristiane ^a   Souto Martinez, Alexandre ^a   Sueli Bonato, Pierina ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Racemization; Stability; Thioridazine; Thioridazine 2 sulfone

Indexed keywords

DRUG METABOLITE; ETHER; PHENOTHIAZINE DERIVATIVE; THIORIDAZINE; THIORIDAZINE 2 SULFONE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CHIRALITY; CONTROLLED STUDY; DRUG DEGRADATION; DRUG SOLUBILITY; DRUG STABILITY; ENANTIOMER; ENANTIOSELECTIVITY; HUMAN; IONIC STRENGTH; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; PH; PLASMA; PRIORITY JOURNAL; RACEMIC MIXTURE; TEMPERATURE; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

ANTIPSYCHOTIC AGENTS; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; SOLUTIONS; STEREOISOMERISM; THIORIDAZINE;

EID: 0037974217     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.10240     Document Type: Article

References (12)

1. Eap CB, Koeb L, Powell K, Baumann P. Determination of the enantiomers of thioridazine, thioridazine-2-sulfone and of the isomeric pairs of the thioridazine-2-sulfoxide and thioridazine-5-sulfoxide in human plasma. J Chromatogr B 1995;669:271-279.
2. Eap CB, Guentert TW, Schäublin-Loldl M, Stabl M, Koeb L, Powell K, Baumann P. Plasma levels of the enantiomers of thioridazine, thioridazine-2-sulfoxide, thioridazine-2-sulfone and thioridazine-5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996;59:322-331.
3. Hale PW, Poklis A. Thioridazine 5-sulfoxide cardiotoxicity in the isolated perfused rat heart. Toxicol Lett 1984;21:1-8.
4. Dahl SG. Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 1982;4:33-40.
5. Axelsson R, Mårtensson E. Side effects of thioridazine and their relationship with the serum concentrations of the drug and its main metabolites. Curr Ther Res 1980;28:463-489.
6. Blake BL, Rose RL, Mailman RB, Levi PE, Hodgson E. Metabolism of thioridazine by microsomal monoxygenases: relative roles of P450 and flavin-containing monoxygenase. Xenobiotica 1995;25:337-393.
7. Eap CB, Koeb L, Baumann P. Artifacts in the analysis of thioridazine and other neuroleptics. J Pharm Biomed Anal 1993;11:451-457.
8. Eap CB, Souche A, Koeb L, Baumann P. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine. Ther Drug Monit 1991;13:356-362.
9. Jortani AS, Poklis A. Determination of thioridazine enantiomers in human serum by sequential achiral and chiral high-performance liquid chromatography. J Anal Toxicol 1993;17:374-377.
10. Jortani AS, Valentour JC, Poklis A. Thioridazine enantiomers in human tissues. Forensic Sci Int 1994;64:165-170.
11. Shah PV, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992;81:309-314.
12. Tucker GT, Lennard MS. Enantiomer specific pharmacokinetics. Pharmacol Ther 1990;45:309-329.